通過核酸接種增强CAR-工程化的T細胞的作用

• 收藏
• 分享

专利权人:

BIONTECH CELL & GENE THERAPIES GMBH;TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GGMBH;TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN

发明人:

SAHIN, Ugur,REINHARD, Katharina,SIMON, Petra,MROZ, Karolina Anna,HOBOHM, Kathleen,皮特拉．西蒙,MROZ, Karolina Anna,卡羅利娜．安娜．姆羅茲,HOBOHM, Kathleen,凱思琳．霍博姆

申请号：

HK18106629.6

公开号：

HK1247098A

申请日:

2018.05.22

申请国别(地区):

HK

年份:

2018

代理人:

摘要：

The present invention generally embraces the treatment of diseases by targeting cells expressing an antigen on the cell surface. In particular the invention relates to a method for stimulating, priming and/or expanding in vivo T cells genetically modified to express a chimeric antigen receptor (CAR) targeted to an antigen, comprising contacting the T cells with the antigen or a variant thereof in vivo. In one embodiment, the antigen or variant thereof is provided by administering a nucleic acid encoding the antigen or variant thereof.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/